Local Control and Clinical Outcome of High-risk Pediatric Neuroblastoma Patients After Receiving Multimodality Treatment and Helical Tomotherapy

Chen, Guann-Yiing; Cheng, Jason Chia‐Hsien; Chen, Yu-Hsuan; Lu, Meng‐Yao; Chang, Hsiu-Hao; Yang, Yung‐Li; Jou, Shiann-Tarng; Hsu, Wen-Ming; Kuo, Sung‐Hsin

doi:10.21873/anticanres.13336

Cited by 17 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to these previous studies, there was no significant difference in survival between NB patients with bone metastasis who underwent surgery at the primary site and those who did not. Typically, radiotherapy is used as a palliative treatment for patients with metastatic NB to relieve local symptoms and control local recurrence (24,25). Hu et al (26) reported that radiotherapy prolongs the survival time of NB patients with brain metastasis.…”

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics and Survival Outcomes in Neuroblastoma With Bone Metastasis Based on SEER Database Analysis

Mao

Huang

2021

Front. Oncol.

View full text Add to dashboard Cite

PurposeClinical features and survival analysis of neuroblastoma (NB) are well explored. However, clinical research of NB patients with bone metastasis is rarely reported. Thus, the current study was performed to analyze the clinical features, survival outcome, and risk factors in those patients.Materials and MethodsWe reviewed the Surveillance, Epidemiology, and End Results (SEER) database to select cases diagnosed with NB with bone metastasis from 2010 to 2016. Overall survival (OS) and cancer-specific survival (CSS) were analyzed through univariate Cox regression analysis. Subsequently, we performed multivariate analysis to determine independent predictors of survival. The Kaplan–Meier method was applied to intuitively show differences in prognostic value between independent risk factors.ResultsWe finally identified 393 NB patients with bone metastasis who were selected for survival analysis. Nearly half of the patients (47.3%) were aged >3 years. The adrenal gland was the primary tumor site, accounting for approximately two thirds of cases (66.2%). The 5-year OS and CSS rates of all patients were 62.1% and 64.1%, respectively. The univariate analysis indicated that age, lung metastasis, and tumor size were significantly associated with OS and CSS. Based on the multivariable analysis, age at 2 and 3 years, lung metastasis, and tumor size >10 cm remained significant negative predictors of OS and CSS.ConclusionFor NB patients with bone metastasis, three independent prognostic risk factors (age, lung metastasis, and tumor size) are helpful to clinicians for predicting prognosis and guiding treatment. Reasonable treatment modalities for these patients should be further investigated to prolong survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics and Survival Outcomes in Neuroblastoma With Bone Metastasis Based on SEER Database Analysis

Mao

Huang

2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…For years, the unique pharmacokinetic characteristics and the mode of action of CUR remain to be of great interest. One study has been reported that only slight changes were observed in peripheral blood of patients after taking 8000 mg of curcumin daily 58 . Similarly, in another study, the concentration of CUR in peripheral circulation was at nmol/L level after receiving 3600 mg of CUR daily in patients with metastatic colon cancer 59 .…”

Section: Resultsmentioning

confidence: 92%

Palmitic acid‐ and cysteine‐functionalized nanoparticles overcome mucus and epithelial barrier for oral delivery of drug

Xie

Jin

et al. 2023

Bioengineering & Transla Med

View full text Add to dashboard Cite

Nanoparticles (NPs) used for oral administration have greatly improved drug bioavailability and therapeutic efficacy. Nevertheless, NPs are limited by biological barriers, such as gastrointestinal degradation, mucus barrier, and epithelial barrier. To solve these problems, we developed the PA‐N‐2‐HACC‐Cys NPs loaded with anti‐inflammatory hydrophobic drug curcumin (CUR) (CUR@PA‐N‐2‐HACC‐Cys NPs) by self‐assembled amphiphilic polymer, composed of the N‐2‐Hydroxypropyl trimethyl ammonium chloride chitosan (N‐2‐HACC), hydrophobic palmitic acid (PA), and cysteine (Cys). After oral administration, the CUR@PA‐N‐2‐HACC‐Cys NPs had good stability and sustained release under gastrointestinal conditions, followed by adhering to the intestine to achieve drug mucosal delivery. Additionally, the NPs could penetrate mucus and epithelial barriers to promote cellular uptake. The CUR@PA‐N‐2‐HACC‐Cys NPs could open tight junctions between cells for transepithelial transport while striking a balance between mucus interaction and diffusion through mucus. Notably, the CUR@PA‐N‐2‐HACC‐Cys NPs improved the oral bioavailability of CUR, which remarkably relieved colitis symptoms and promoted mucosal epithelial repair. Our findings proved that the CUR@PA‐N‐2‐HACC‐Cys NPs had excellent biocompatibility, could overcome mucus and epithelial barriers, and had significant application prospects for oral delivery of the hydrophobic drugs.

show abstract

“…273 Curcumin derived from curcuma longa rhizome (Turmeric) has passed human phase I and phase II clinical trials for cancer and its high safety and no dose-limiting toxicity enabled progression to phase III clinical in patients with metastatic colon cancer. [274][275][276] Another natural plant-derived steroid saponin, dioscin, has been shown to promote CDH1-mediated polyubiquitination and degradation of SKP2 and a significant reduction in the cell growth of colorectal cancer. 277 4.1.3 FBXW7 and CRL FBXW7 as a tumour suppressor is mutated or inhibited in human cancers with high frequency.…”

Section: Skp2mentioning

confidence: 99%

“…Additionally, the naturally occurring compounds, Curcumin, lycopene and quercetin exhibit anti‐cancer effects by down‐regulating SKP2 expression leading to cell cycle arrest 273 . Curcumin derived from curcuma longa rhizome (Turmeric) has passed human phase I and phase II clinical trials for cancer and its high safety and no dose‐limiting toxicity enabled progression to phase III clinical in patients with metastatic colon cancer 274–276 . Another natural plant‐derived steroid saponin, dioscin, has been shown to promote CDH1‐mediated polyubiquitination and degradation of SKP2 and a significant reduction in the cell growth of colorectal cancer 277 …”

Section: Targeting E3 Ubiquitin Ligase In the Cancer Hallmark Pathwaymentioning

confidence: 99%

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

Sampson

Wang

Otkur

et al. 2023

Clinical & Translational Med

View full text Add to dashboard Cite

Ubiquitination is one of the most important post‐translational modifications which plays a significant role in conserving the homeostasis of cellular proteins. In the ubiquitination process, ubiquitin is conjugated to target protein substrates for degradation, translocation or activation, dysregulation of which is linked to several diseases including various types of cancers. E3 ubiquitin ligases are regarded as the most influential ubiquitin enzyme owing to their ability to select, bind and recruit target substrates for ubiquitination. In particular, E3 ligases are pivotal in the cancer hallmarks pathways where they serve as tumour promoters or suppressors. The specificity of E3 ligases coupled with their implication in cancer hallmarks engendered the development of compounds that specifically target E3 ligases for cancer therapy. In this review, we highlight the role of E3 ligases in cancer hallmarks such as sustained proliferation via cell cycle progression, immune evasion and tumour promoting inflammation, and in the evasion of apoptosis. In addition, we summarise the application and the role of small compounds that target E3 ligases for cancer treatment along with the significance of targeting E3 ligases as potential cancer therapy.

show abstract

Local Control and Clinical Outcome of High-risk Pediatric Neuroblastoma Patients After Receiving Multimodality Treatment and Helical Tomotherapy

Cited by 17 publications

References 0 publications

Clinical Characteristics and Survival Outcomes in Neuroblastoma With Bone Metastasis Based on SEER Database Analysis

Clinical Characteristics and Survival Outcomes in Neuroblastoma With Bone Metastasis Based on SEER Database Analysis

Palmitic acid‐ and cysteine‐functionalized nanoparticles overcome mucus and epithelial barrier for oral delivery of drug

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

Contact Info

Product

Resources

About